Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Neovacs S.A. is a French biotechnology company specializing in the development of therapeutic vaccines, primarily targeting autoimmune, inflammatory, allergy, and cancer diseases. The company’s core innovation lies in its proprietary "Kinoid" technology platform, which enables active immunotherapy by regulating the overproduction of cytokines involved in disease processes. Notable products in its pipeline include the IFNa Kinoid vaccine, for which clinical trials are underway for lupus erythematosus and dermatomyositis, and an IL-4/IL-13 Kinoid vaccine in preclinical stages for allergy treatment. Beyond R&D, Neovacs also leverages its expertise through investments in other innovative biotech and medtech firms. Founded in 1993 and headquartered in Paris, Neovacs plays a significant role in advancing therapeutic vaccine technology within the healthcare and biotechnology sectors.
The business is unprofitable at the operating level (-3731.82% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 31.4% YoY. Margins deteriorated 1426.7pp alongside, both lines moving the wrong way.
ROIC dropped from -19.29% to -31.87%, capital efficiency is deteriorating. Negative free cash flow of -€4M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€366K
▼ -31.4% YoY
Net Income (TTM)
-€33M
▼ -276.4% YoY
Op. Margin
-3731.82%
▼ -1426.7pp YoY
ROIC
-31.87%
▼ -12.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€4M
▼ -73.8% YoY
Op. Cash Flow (TTM)
-€4M
▼ -88.1% YoY
Net Debt
-€205K
Net Cash Position
Cash & Equiv.
€435K
3Y CAGR: +153.1%
Continue Research